Changqing Xie

1.4k total citations
48 papers, 745 citations indexed

About

Changqing Xie is a scholar working on Oncology, Surgery and Cancer Research. According to data from OpenAlex, Changqing Xie has authored 48 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Surgery and 16 papers in Cancer Research. Recurrent topics in Changqing Xie's work include Cancer Immunotherapy and Biomarkers (15 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Changqing Xie is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Changqing Xie collaborates with scholars based in United States, China and Malaysia. Changqing Xie's co-authors include Tim F. Greten, Bradford J. Wood, Jianyang Fu, Gagandeep Brar, David E. Kleiner, Nicole McGrath, Xin Wang, Austin G. Duffy, Seth M. Steinberg and Jihye Lee and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Changqing Xie

47 papers receiving 737 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Changqing Xie United States 14 465 183 165 147 129 48 745
Yongwoo David Seo United States 12 468 1.0× 210 1.1× 130 0.8× 139 0.9× 99 0.8× 25 709
Rikke Løvendahl Eefsen Denmark 11 375 0.8× 165 0.9× 158 1.0× 54 0.4× 179 1.4× 32 624
Tianqiang Jin China 10 292 0.6× 246 1.3× 247 1.5× 54 0.4× 95 0.7× 19 681
Rekha Samuel United States 9 261 0.6× 196 1.1× 280 1.7× 86 0.6× 113 0.9× 9 706
Hongbing Shi China 12 321 0.7× 204 1.1× 159 1.0× 80 0.5× 66 0.5× 25 626
Annabelle Vogt Germany 15 249 0.5× 216 1.2× 220 1.3× 122 0.8× 231 1.8× 25 741
Magali Castells France 9 254 0.5× 223 1.2× 279 1.7× 71 0.5× 84 0.7× 9 723
Imane El Dika United States 13 214 0.5× 75 0.4× 207 1.3× 81 0.6× 178 1.4× 30 573
Michitaka Nakano Japan 14 527 1.1× 217 1.2× 198 1.2× 67 0.5× 40 0.3× 33 764
Hengkang Liu China 6 263 0.6× 280 1.5× 264 1.6× 76 0.5× 51 0.4× 6 637

Countries citing papers authored by Changqing Xie

Since Specialization
Citations

This map shows the geographic impact of Changqing Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changqing Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changqing Xie more than expected).

Fields of papers citing papers by Changqing Xie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changqing Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changqing Xie. The network helps show where Changqing Xie may publish in the future.

Co-authorship network of co-authors of Changqing Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Changqing Xie. A scholar is included among the top collaborators of Changqing Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changqing Xie. Changqing Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Wang‐Zhong, Ying Huang, Xiaobin Zhu, et al.. (2024). Single‐cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma. Clinical and Translational Medicine. 14(10). e70061–e70061. 2 indexed citations
3.
Monge, Cecilia, Changqing Xie, Yuta Myojin, et al.. (2024). Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma. Cancer Medicine. 13(3). e6912–e6912. 6 indexed citations
4.
Wang, Limin, Marshonna Forgues, Shay Behrens, et al.. (2024). Lineage and ecology define liver tumor evolution in response to treatment. Cell Reports Medicine. 5(2). 101394–101394. 3 indexed citations
5.
Liu, Guoying, Lin Wang, Jianwei Wang, et al.. (2024). Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial. Nature Communications. 15(1). 1029–1029. 9 indexed citations
6.
Monge, Cecilia, Changqing Xie, Yuta Myojin, et al.. (2023). Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. 11(2). e005640–e005640. 46 indexed citations
7.
Lu, Xinjun, Benjamin L. Green, Changqing Xie, Chao Liu, & Xin Chen. (2023). Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma. JHEP Reports. 5(7). 100723–100723. 9 indexed citations
8.
Myojin, Yuta, Justin McCallen, Chi Ma, et al.. (2023). Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers. JHEP Reports. 6(1). 100959–100959. 12 indexed citations
9.
Wang, Xin Wei, et al.. (2023). Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver. Journal of Hepatocellular Carcinoma. Volume 10. 745–752. 5 indexed citations
10.
Lu, Nian, Wei‐Xiong Xia, Ying Huang, et al.. (2023). Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study. EClinicalMedicine. 62. 102136–102136. 9 indexed citations
11.
Xie, Changqing, et al.. (2023). The current landscape of therapies for hepatocellular carcinoma. Carcinogenesis. 44(7). 537–548. 14 indexed citations
12.
Xie, Changqing, Bernadette Redd, Bradford J. Wood, et al.. (2023). A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 41(4_suppl). TPS624–TPS624. 11 indexed citations
13.
Wang, Xin, Jianyang Fu, Michael C. Kelly, et al.. (2023). Single-cell RNA sequencing reveals cancer stem-like cells and dynamics in tumor microenvironment during cholangiocarcinoma progression. Frontiers in Cell and Developmental Biology. 11. 1250215–1250215. 3 indexed citations
14.
Wang, Xin, et al.. (2023). Reciprocal Interaction of Cancer Stem Cells of Cholangiocarcinoma with Macrophage. Stem Cell Reviews and Reports. 19(6). 2013–2023. 9 indexed citations
15.
Fu, Jianyang, Xin Wang, Jihye Lee, et al.. (2022). Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing. Stem Cells International. 2022. 1–14. 12 indexed citations
16.
Monge, Cecilia, Erica C. Pehrsson, Changqing Xie, et al.. (2022). A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. The Oncologist. 27(3). e273–e285. 32 indexed citations
17.
Xie, Changqing, Austin G. Duffy, Gagandeep Brar, et al.. (2020). Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 26(10). 2318–2326. 65 indexed citations
18.
Chen, Xiaohong, et al.. (2020). LncRNA ZNF667-AS1 Promotes ABLIM1 Expression by Adsorbing microRNA-1290 to Suppress Nasopharyngeal Carcinoma Cell Progression. SHILAP Revista de lepidopterología. 1 indexed citations
19.
McGrath, Nicole, et al.. (2020). Targeting cancer stem cells in cholangiocarcinoma (Review). International Journal of Oncology. 57(2). 397–408. 20 indexed citations
20.
Li, Wang‐Zhong, Shu‐Hui Lv, Guoying Liu, et al.. (2020). Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study. International Journal of Radiation Oncology*Biology*Physics. 109(1). 120–130. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yongwoo David Seo Breakdown of academic impact, for papers by Rikke Løvendahl Eefsen Breakdown of academic impact, for papers by Tianqiang Jin Breakdown of academic impact, for papers by Rekha Samuel Breakdown of academic impact, for papers by Hongbing Shi Breakdown of academic impact, for papers by Annabelle Vogt Breakdown of academic impact, for papers by Magali Castells Breakdown of academic impact, for papers by Imane El Dika Breakdown of academic impact, for papers by Michitaka Nakano Breakdown of academic impact, for papers by Hengkang Liu
Rankless by CCL
2026